False-Negative and False-Positive Results in FDG-PET and PET/CT in Breast Cancer
Authors:
- 1 July 2009
- journal article
- review article
- Published by Elsevier in PET Clinics
- Vol. 4 (3) , 289-298
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- 64Cu-Labeled Peptide for PET of Breast Carcinomas Expressing the Thomsen-Friedenreich Carbohydrate AntigenJournal of Nuclear Medicine, 2011
- Breast Cancer Staging in a Single Session: Whole-Body PET/CT MammographyJournal of Nuclear Medicine, 2008
- Clinicopathologic factors associated with false negative FDG–PET in primary breast cancerBreast Cancer Research and Treatment, 2006
- Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survivalCancer, 2004
- Biological characterisation of breast cancer by means of PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- FDG uptake in breast cancer: correlation with biological and clinical prognostic parametersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission TomographyJournal of Clinical Oncology, 2002
- Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and LimitationsJournal of Clinical Oncology, 2000
- Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.Radiology, 1993
- Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.Radiology, 1991